Details of the Drug-Related molecule(s) Expression Atlas
General Information of Drug (ID: DM32MIE)
Drug Name | ||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
BRN 0160817; 6-Hydroxy-N,N-dimethyltryptamine; 1476-33-1; INDOL-6-OL, 3-(2-(DIMETHYLAMINO)ETHYL)-; CHEMBL382750; 3-(2-dimethylaminoethyl)-1H-indol-6-ol; 1H-Indol-6-ol, 3-[2-(dimethylamino)ethyl]-; 3-(2-Dimethylamino-ethyl)-1H-indol-6-ol; 5-22-12-00067 (Beilstein Handbook Reference); 6-hydroxy-N-dimethyltryptamine; AC1L257Q; DTXSID70163752; BDBM50171259; AKOS023092717; LS-83678
|
|||||||||||||||||||
Indication |
|
|||||||||||||||||||
Cross-matching ID | ||||||||||||||||||||
Molecule(s) Related to This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs
|
||||||||||||||||||||||||||||||||||||||||
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs | ||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue
The Studied Disease | Discovery agent | |||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue | ||||||||||||||||||||||||||||||||||||||||||||||||||||||